Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers
Drugs in Context · 18.12.2024 · 13 · 1-10
DOI: 10.7573/dic.2024-10-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 18.12.2024. Verfasst von Hema Sundaram und 6 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice, Rockville, Maryland; Private Practice, Fairfax, Virginia, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Aliaxin fillers (HAALI), produced by IBSA Farmaceutici Italia SrL (Italy), are biodegradable, non-pyrogenic, 1,4-butanediol diglycidyl ether cross-linked hyaluronic acid (HA) hydrogels. The formulations are tailored for different clinical indications, ensuring precise and natural outcomes. Their cohesivity and tissue integration capabilities are associated with relatively few adverse events (AEs), supporting their widespread use in aesthetic treatments. This article examines the real-world safety profile of HAALI fillers derived from worldwide post-marketing surveillance data.
Methods
Post-marketing surveillance was registered by the manufacturer from January 2018 to September 2023. During this period, product complaints were globally gathered from healthcare practitioners and consumers, relating to technical issues or safety and product-related adverse events.
Results
No discernible trend or substantial escalation in AEs across the entire product range were observed during the surveillance period (p>0.05). No statistically significant increases (p>0.05) in the frequency or severity of safety incidents and AEs were observed. The most frequently observed AEs were oedema (26%) and swelling (19%).
Conclusion
The analysed data further support and confirm the high safety profile of the HAALI fillers for different approaches in aesthetic medicine. This evaluation also highlights the importance of post-marketing analysis by continuing to foster a robust understanding of products currently used in daily clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Private Practice, Rockville, Maryland; Private Practice, Fairfax, Virginia, USA.
- Division of Musculoskeletal and Skin Diseases, University of Manchester, Manchester, UK.
- Medikas Clinic, Somerset, Bristol, UK.
- Private Practice, Verona, Italy.
- Dameto Clinics International, Campanet, Spain.
- Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, University of Girona, Girona, Spain.
Zitieren
APA
Sundaram, H., Molina, B., Buttura da Prato, E., Siquier-Dameto, G., Zazzaron, M., Cigni, C., & Grimolizzi, F. (2024). Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers. Drugs in Context, 13, 1-10. https://doi.org/10.7573/dic.2024-10-6
Vancouver
Sundaram H, Molina B, Buttura da Prato E, Siquier-Dameto G, Zazzaron M, Cigni C, et al. Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers. Drugs in Context. 2024;13:1-10. doi:10.7573/dic.2024-10-6
BibTeX
@article{Sundaram2024,
author = {Sundaram, Hema and Molina, Beatriz and Buttura da Prato, Editta and Siquier-Dameto, Gabriel and Zazzaron, Michela and Cigni, Clara and Grimolizzi, Franco},
title = {Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HAALI BDDE cross-linked hyaluronic acid fillers},
journal = {Drugs in Context},
year = {2024},
volume = {13},
pages = {1--10},
doi = {10.7573/dic.2024-10-6}
}
EUVIMED